-

KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting

PITTSBURGH--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL.

VET3-TGI is a novel oncolytic immunotherapy which is designed to systemically target and selectively kill tumor cells while also expressing an immuno-stimulatory transgene payload consisting of interleukin-12 and a TGFbeta inhibitor.

Share

The presentation will focus on the company’s clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, advanced solid tumors. VET3-TGI is a novel oncolytic immunotherapy which is designed to systemically target and selectively kill tumor cells while also expressing an immuno-stimulatory transgene payload consisting of interleukin-12 and a TGFbeta inhibitor.

Details on the poster presentation are below:

Presentation Title: Mechanisms of synergy between TGF-beta inhibitor and IL12 expression from the systemically deliverable clinical oncolytic immunotherapy VET3-TGI
Abstract Number: 484
Session Date & Time: Sunday, April 27, 2025; 2-5 pm
Presenter: Stephen Thorne, PhD, Co-founder and Chief Scientific Officer, KaliVir Immunotherapeutics

About KaliVir Immunotherapeutics, Inc.

KaliVir Immunotherapeutics is a clinical-stage biotechnology company at the forefront of developing next-generation oncolytic immunotherapies. By harnessing the unique advantages of the vaccinia platform, KaliVir engineers optimized viral backbones to create innovative candidates for cancer treatment. The Company's proprietary Vaccinia Enhanced Template (VET™) platform integrates multiple genetic modifications, allowing for the systemic delivery of oncolytic vaccinia candidates and the targeted expression of therapeutic transgenes within tumors.

The Company is actively expanding its pipeline using the VET™ platform, with its capabilities validated through strategic global partnerships with Astellas Pharma and Roche. Currently, the Company has two product candidates in Phase 1 clinical trials: ASP1012, exclusively licensed and led by Astellas Pharma, and its internal lead candidate, VET3-TGI. With multiple therapeutic candidates progressing through clinical development, KaliVir is positioned as a leader in innovative cancer therapies.

Headquartered in Pittsburgh, Pennsylvania, KaliVir is committed to revolutionizing cancer treatment. For more information, visit www.kalivir.com.

Contacts

Media:
Lauren Arnold
LA Communications
Lauren@LACommunications.net

Industry:

KaliVir Immunotherapeutics, Inc.

Release Versions
English

Contacts

Media:
Lauren Arnold
LA Communications
Lauren@LACommunications.net

More News From KaliVir Immunotherapeutics, Inc.

KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors

PITTSBURGH--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical trial collaboration and supply agreement with Roche to evaluate VET3-TGI, a novel oncolytic immunotherapy developed using KaliVir’s proprietary Vaccinia Enhanced Template (VET™) platform, in combination with Roche’s atezolizumab (Tecentriq®). The collaboration will support the expansion of KaliVir’s...

KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors

PITTSBURGH, Pa.--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the successful completion of the first cohort in the intravenous (IV) infusion arm of its STEALTH-001 (NCT06444815) clinical study, a Phase 1/1b clinical trial of VET3-TGI for patients with incurable, advanced solid tumors. Patients received VET3-TGI, the Company’s lead oncolytic immunotherapy cand...

KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors

PITTSBURGH--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the successful completion of the first cohort in its STEALTH-001 study, a Phase 1/1b clinical trial of VET3-TGI for patients with incurable, advanced solid tumors. VET3-TGI is a novel oncolytic immunotherapy designed to target and selectively kill tumor cells while also expressing an immuno-stimulatory...
Back to Newsroom